Skip to content

BeneChill, Inc. Announces Positive Results from COOLHEAD Clinical Study

Intranasal Evaporative Cooling Benefits Migraine Patients
San Diego, CA – February 4, 2015 – BeneChill, Inc. (“BeneChill”, the “Company”)
announced positive results from the COOLHEAD Clinical Study. The purpose of the
study was to determine the effectiveness of intranasal evaporative cooling for the
treatment of acute migraine headaches.
The open-label, observational study consisted of 15 adult patients (M=3, F=12) with
an average age of 43 years. All patients satisfied the International Classification of
Headache Disorders (ICHD 2) criteria for either episodic (with or without aura), or
chronic migraine. Patients in this trial were categorized as having severe migraine
with 93% recording a normal historical duration of pain and symptoms of more than
24 hours, when using standard treatments, while 46% of the patients had typical
migraines lasting up to 72 hours. The historical baseline of migraine Pain Severity
(VAS 0-10 with 0 = no pain/discomfort and 10 = severe pain/discomfort) for this
patient group averaged a score of 8, with modes of 9 and 10. All patients stated
that they had multiple migraine attacks per month.
The study protocol was designed for patients to receive 1 treatment per migraine
incident. Patients could be treated for multiple migraines throughout the study’s
duration. A total of 20 treatments were provided (12 patients received 1
treatment, 3 patients received 2 treatments, and 1 patient received 3 treatments).
BeneChill’s products consist of a portable control unit, a nasal catheter and a
bottle of cooling fluid. A maximum intranasal cooling period of 20 minutes was
allowed per treatment; however, the average treatment time delivered was 15
minutes of cooling.

The study was investigator initiated and led by consultant neurologist, Dr. Jitka
Vanderpol. The site was the Penrith Community Hospital, part of the Cumbria
Partnership NHS Foundation Trust, located in the North West of the United
Primary endpoints for the COOLHEAD Clinical Study were the reduction in pain and
in associated symptoms. Results were positive for both. Complete or partial pain
relief was reported in 13 of the patients (87%). Treatments offered the patients
either complete relief (40%) or partial relief (50%) from pain and associated
symptoms after a mean treatment duration of 15 minutes. Furthermore, 90% of all
patients experienced either full or partial relief at 2 hours post treatment. Eightyseven
percent (87%) experienced sustained relief 24 hours post treatment.
Additionally, BeneChill’s migraine therapy reported no major adverse side effects.
In comparison to current relief therapies (including triptan drugs, cool packs, and
other prescription analgesics), 60% of patients reported that BeneChill’s intranasal
cooling offered better results. Twenty-six percent (26%) stated that intranasal
cooling was as good as their current medication, but with less side effects. The
patients who preferred intranasal cooling therapy cited that their preference was
based on intranasal cooling providing significantly faster relief from pain and
symptoms than their existing medication and/or remedies. The patients who
usually take triptan medications also noted that they did not suffer from any of the
debilitating side effects that they encounter after taking their normal rescue
medication, which ”knocks me out”.
“The COOLHEAD Study’s findings are very promising. Our initial experience has
demonstrated that intranasal cooling is safe, effective, quick and well tolerated.
While intranasal cooling is a novel approach, it has been shown to offer faster
relief for those suffering from severe, recurrent, and long-lasting migraines.
Furthermore, the intranasal cooling therapy has additional benefits in that it is
comfortable for the patient and is not associated with numerous negative side
effects experienced with use of abortive triptan drugs. A larger, multi-site clinical
trial will be planned to provide further evidence of the benefits from this
application,” stated Fred Colen, Chief Executive Officer of BeneChill.

About BeneChill, Inc.
BeneChill, Inc. is a medical device company established in 2003 to develop, manufacture,
and sell novel rapid cooling products to improve clinical outcomes. BeneChill’s lead
product, the RhinoChill® IntraNasal Cooling System (also referred to as the RhinoChill®
System, “RhinoChill®”, or the “System”), is designed to deliver targeted, effective and
therapeutically beneficial cooling to the nasal cavity and the brain (and to the body via the
cooled brain, if so desired). BeneChill’s technology is intended to protect the brain
through reduction of brain oxygen demand, reduction of brain swelling, and minimizing the
impact of hypoxic brain injury significantly earlier and in a more effective manner
compared to current methods. Utilizing a lightweight, portable system design and unique
intra-nasal, catheter-based delivery of a quickly evaporating coolant, BeneChill enables a
range of medical professionals including first responders, emergency room personnel, and
surgeons a unique opportunity to start protecting the brain. BeneChill’s treatment can be
used during Cardiac Arrest, potentially during Traumatic Brain Injury and may be
applicable for other surgical procedures. BeneChill’s cooling technology, however, is not
only designed for brain protection applications for unconscious or sedated patients, it is
also suitable for applications on conscious patients where a local, short duration cooling of
the nasal cavity is of therapeutic benefit, such as for the treatment of acute migraine.
BeneChill is headquartered in San Diego, CA with European locations near Zürich,
Switzerland and Düsseldorf, Germany. BeneChill products, while CE marked in Europe for
cooling applications are not FDA approved and not available in the US. For further
information please visit
Safe Harbor:
Certain matters discussed in this release may constitute forward looking statements for the
purposes of the Federal Securities Laws, and as such, may involve known and unknown risk.
Uncertainties and other factors may cause actual results, performance or activities of
BeneChill, Inc. to be materially different from future results of performance or
achievements expressed or implied by such forward looking statements. Additional
information concerning factors that could cause actual results to be materially different
than those in forward looking statements can be found in BeneChill, Inc.’s filings with the
Securities and Exchange Commission (SEC). All forward-looking statements are expressly
qualified in their entirety by these cautionary statements.

BeneChill,Inc. Contact:
Fred Colen, Chief Executive Officer
(858) 695-8118
Investor Relations Contact:
Jennifer K. Zimmons, Ph.D., Investor Relations
(917) 214-3514

Source: BeneChill